Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Fibrocell Science (FCSC)

Fibrocell Science (FCSC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Fibrocell Science 405 EAGLEVIEW BOULEVARD EXTON PA 19341 USA

fibrocell.com P: 484-713-6000

Description:

Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell's most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company's lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma.

Key Statistics

Overview:

Market Capitalization, $K 29,275
Shares Outstanding, K 9,758
Annual Sales, $ 0 K
Annual Net Income, $ -10,280 K
Last Quarter Sales, $ 1,020 K
Last Quarter Net Income, $ -7,200 K
60-Month Beta 1.67
% of Insider Shareholders 1.10%
% of Institutional Shareholders 36.72%
Float, K 9,651
% Float 98.90%

Growth:

1-Year Return 48.51%
3-Year Return -69.70%
5-Year Return -92.54%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth 90.61%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 11/19/19
Earnings Per Share ttm 0.18
EPS Growth vs. Prev Qtr -135.71%
EPS Growth vs. Prev Year -42.86%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-5 on 05/25/18

FCSC Ratios

Ratio
Price/Earnings ttm 16.67
Price/Earnings forward 30.00
Price/Earnings to Growth N/A
Return-on-Equity % 23.10%
Return-on-Assets % 10.56%
Profit Margin % 0.00%
Debt/Equity 0.47
Price/Sales 1.28
Price/Cash Flow N/A
Price/Book 2.73
Book Value/Share 1.10
Interest Coverage -12.35
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar